Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Xiaochun Wang,1,2 David Goldstein,3 Philip J Crowe,1,2 Jia-Lin Yang1,2 1Department of Surgery, 2Sarcoma and Nanooncology Group, Adult Cancer Program, Lowy Cancer Research Centre, 3Department of Medical Oncology, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sy...

Full description

Bibliographic Details
Main Authors: Wang X, Goldstein D, Crowe PJ, Yang JL
Format: Article
Language:English
Published: Dove Medical Press 2016-09-01
Series:OncoTargets and Therapy
Subjects:
EGFR/HER
tyrosine kinase inhibitors (TKIs)
NSCLC
EGFR mutations
acquired resistance
Online Access:https://www.dovepress.com/next-generation-egfrher-tyrosine-kinase-inhibitors-for-the-treatment-o-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/next-generation-egfrher-tyrosine-kinase-inhibitors-for-the-treatment-o-peer-reviewed-article-OTT

Similar Items